Cyclosporin Monitoring in Australasia: 2002 Update of Consensus Guidelines

R.G. Morris, Kenneth Ilett, S.E. Tett, J.E. Ray, R.O. Fullinfaw, R. Cooke, S. Cook

Research output: Contribution to journalArticlepeer-review

31 Citations (Scopus)


Therapeutic drug monitoring of cyclosporin (CsA) has been established as part of the routine clinical treatment of patients following organ transplantation for more than 20 years, and based on contemporary knowledge, many consensus guidelines have been published to assist clinics and laboratories attain optimal strategies for patient care. This article addresses the newer directions in CsA monitoring, with particular reference to the Australasian situation that has evolved since the 1993 Australasian guideline (1). These changes have included the introduction of alternative assay methodologies, changed CsA formulation from Sandimmun to Neoral throughout Australasia, and alternatives to trough concentration (C0) monitoring, especially 2-hour concentration (C2) monitoring and associated validated dilution protocols to accurately quantitate the higher whole blood CsA concentrations. The revision was prepared following a recent survey of all Australasian CsA-monitoring laboratories (2) where discordant practices were evident.
Original languageEnglish
Pages (from-to)677-688
JournalTherapeutic Drug Monitoring
Publication statusPublished - 2002


Dive into the research topics of 'Cyclosporin Monitoring in Australasia: 2002 Update of Consensus Guidelines'. Together they form a unique fingerprint.

Cite this